跳到主要內容

臺灣博碩士論文加值系統

(18.97.14.82) 您好!臺灣時間:2025/02/19 10:55
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:吳佳恩
研究生(外文):Chia-Eng Wu
論文名稱:探討免疫分化基因之表現:比較人類體細胞、多能性幹細胞與分化後細胞之差異性
論文名稱(外文):Exploration of global immune-related genes of human somatic cells, pluripotent stem cells and their differentiated derivatives
指導教授:何弘能何弘能引用關係
指導教授(外文):Hong-Nerng Ho
口試日期:2017-07-07
學位類別:博士
校院名稱:國立臺灣大學
系所名稱:免疫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2017
畢業學年度:105
語文別:英文
論文頁數:122
中文關鍵詞:人類多能性幹細胞免疫性雷帕黴素複合物的哺乳動物移植
外文關鍵詞:Human pluripotent stem cellsimmunogenicitymTORtransplantation
相關次數:
  • 被引用被引用:0
  • 點閱點閱:246
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
人類多能性幹細胞包括胚胎幹細胞(human embryonic stem cell; hESC)與誘導型多能幹細胞(induced pluripotent stem cell; iPSC),過去被視為是臨床應用上分化成各種細胞的主要來源。人類胚胎幹細胞經分離囊胚細胞當中的內細胞群得以建立,而誘導型多能幹細胞為利用送入特定因子:Oct4, Sox2, Klf4, 與 c-Myc於體細胞中,使該細胞變成多能性幹細胞。之前研究顯示,人類多能性幹細胞可能透過減少主要組織相容性複合蛋白達成逃避免疫及降低免疫反應。然而研究多能性幹細胞是否引起免疫反應的結果具有爭議性。部分研究指出,多能性幹細胞確實在小鼠模式中引起免疫反應。為了提升多能性幹細胞的臨床應用,更重要的課題是探討已分化幹細胞的免疫性。本研究比較人類胚胎幹細胞、誘導型多能幹細胞與體細胞的免疫相關基因表現,並從中發現可能影響引起免疫反應的候選基因。藉由比較已分化幹細胞、未分化幹細胞以及包括真皮乳頭細胞、卵巢顆粒細胞與包皮纖維細胞等三種人類體細胞的免疫相關基因表現。結果顯示以下基因:CD24, GATA3, PROM1, THBS2, LY96, IFIT3, CXCR4, IL1R1, FGFR3, IDO1和KDR,其表現量之多寡與我們所選定的免疫相關基因相符。其中CD24, PROM1, FGFR3, IDO1和KDR基因於未分化幹細胞表現量較體細胞高,LY96, IFIT3和IL1R1基因於未分化幹細胞表現量較體細胞低。GATA3, CXCR4, PROM1, FGFR3和KDR基因於分化幹細胞表現量較體細胞高,THBS2基因於分化幹細胞表現量較體細胞低。雷帕黴素複合物的哺乳動物靶(mammalian target of rapamycin; mTOR)扮演調控人類免疫重要角色,雷帕黴素(rapamycin)更是器官移植時重要的免疫抑制劑。我們進一步利用雷帕黴素(rapamycin)探討雷帕黴素複合物的哺乳動物靶在已分化幹細胞中的角色。結果顯示抑制雷帕黴素複合物的哺乳動物靶訊息傳遞會導致對已分化幹細胞之免疫反應顯著降低。雷帕黴素處理之已分化幹細胞使CD24表現量降低,此結果顯示抑制雷帕黴素複合物的哺乳動物靶訊息傳遞調控CD24基因表現。進一步應用慢病毒轉導shRNA抑制CD24與GATA3表現導致已分化幹細胞中不同程度的調控免疫相關基因表現。此外,我們以混合淋巴細胞反應法探討對已分化幹細胞引起之免疫反應,結果顯示包含神經細胞等缺乏CD24與GATA3之已分化幹細胞,活化人類淋巴球能力較差。藉由分析免疫相關基因轉錄組,我們發現人類多能性幹細胞有分化為具有免疫表現型細胞的趨勢。因此,本研究發現的免疫相關候選基因,例如本研究提出的CD24與GATA3,可作為日後臨床應用之重要標的。
Human pluripotent stem cells (hPSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), represent a potentially unlimited cell sources for clinical applications. hESCs are derived from the inner cell mass (ICM) of the early stage human blastocyst. The iPSCs are reprogrammed from somatic cells to pluripotent cells by transduction of the factors Oct4, Sox2, Klf4, and c-Myc. Previous studies have suggested that hPSCs may benefit from immune privilege and limited immunogenicity reflected by the reduced expression of major histocompatibility complex class (MHC)-related molecules. However, the immunogenicity of PSCs is still controversial. Some evidence shows that PSCs do activate immune response in immunocompetent mice. Moreover, before the application of hPSCs for clinical application, the most important issue is the immunogenicity of cells derived from PSCs. Here, we investigated the global immune-related gene expression profiles of hESCs, hiPSCs and somatic cells, and identified candidate immune-related genes that may alter their immunogenicity. The expression levels of global immune-related genes were determined by comparing undifferentiated and differentiated stem cells and in three types of human somatic cells: dermal papilla cells, ovarian granulosa cells, and foreskin fibroblast cells. We identified the differentially-expressed genes CD24, GATA3, PROM1, THBS2, LY96, IFIT3, CXCR4, IL1R1, FGFR3, IDO1, and KDR which overlapped with selected immune-related gene lists. Among these genes, CD24, PROM1, FGFR3, IDO1 and KDR were consistently significant upregulated, and LY96, IFIT3 and IL1R1 were consistently significant downregulated in undifferentiated stem cells compared with somatic cells. The genes GATA3, CXCR4, PROM1, FGFR3 and KDR were consistently upregulated, and only THBS2 was uniformly downregulated in 15-day differentiated stem cells compared with somatic cells. The mammalian target of rapamycin complex (mTOR) signaling pathway has been identified as a key mediator of human immunity and has been leveraged as a therapeutic strategy in tissue transplantation by using rapamycin. In further analyses, mTOR signaling was investigated in the differentiated stem cells following treatment with rapamycin. We found that the inhibition of mTOR signal pathways significantly downregulated immunogenicity of differentiated stem cells. CD24 expression was significantly reduced by rapamycin treatment in the differentiated stem cells. The data indicated mTOR pathway regulated CD24 in stem cell derivatives. Furthermore, reduced expression of CD24 and GATA3 by lentiviral transduction with specific shRNAs in stem cell derivatives leaded to differential regulation of multiple immune-related genes. We also tested the immune responses induced by differentiated stem cells by mixed lymphocyte reactions. We found that CD24- and GATA3-deficient differentiated stem cells including neural lineage cells had limited abilities to activate human lymphocytes. By analyzing the transcriptome signature of immune-related genes, we showed a tendency of the hPSCs to differentiate toward an immune cell phenotype. Taken together these data indicated candidate immune-related genes, in our case, CD24 and GATA3 that might constitute a valuable target for clinical applications.
ABSTRACT…………………………………………………………. I
ABSTRACT IN CHINESE……………………………………………… III
CONTENTS………………………………………………………………… V
CONTENTS OF FIGURES AND TABLES………………………………. VI

INTRODUCTION…………………………………………………………. 1
MATERIALS AND METHODS…………………………………………... 17
RESULTS………………………………………………………………….... 30
DISCUSSION………………………………………………………………. 42
FIGURES AND TABLES………………………………………………… 60
REFFERENCES……………………………………………………………. 106
APPENDIX…………………………………………………………………... 122
1.Wobus, A.M. and K.R. Boheler, Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev, 2005. 85: p. 635-78.
2.Thomson, J.A., et al., Embryonic stem cell lines derived from human blastocysts. Science, 1998. 282: p. 1145-47.
3.Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126: p. 663-76.
4.Takahashi, K. and S. Yamanaka, A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol, 2016. 17: p.183-93.
5.Shi, Y., et al., Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discovery, 2017. 16: p. 115-30.
6.Kimbrel, E.A. and R. Lanza, Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discovery, 2015. 14: p. 681-92.
7.Trounson, A. and C. McDonald, Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell, 2015. 17: p. 11-22.
8.Mandai, M., et al., Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med, 2017. 376: p. 1038-46.
9.Cyranoski, D., Japanese man is first to receive ‘reprogrammed’ stem cells from another person. Nature, 2017.21730.
10.Trounson, A. and N.D. DeWitt, Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol, 2016. 17: p. 194-200.
11.Tucker, B.A., et al., Duplication of TBK1 stimulates autophagy in iPSC-derived retinal cells from a patient with normal tension glaucoma. J Stem Cell Res Ther, 2014. 3: p. 161-.
12.Lee, G., et al., Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotech, 2012. 30: p. 1244-48.
13.Li, L., et al., Human embryonic stem cells possess immune-privileged properties. Stem Cells, 2004. 22: p. 448-56.
14.Drukker, M., et al., Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells, 2006. 24: p. 221-9.
15.Bonde, S., K.M. Chan, and N. Zavazava, ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS One, 2008. 3: p. e3212.
16.Robertson, N.J., et al., Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A, 2007. 104: p. 20920-5.
17.Chen, H.F., et al., Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives. Cell Transplant, 2015. 24: p. 845-64.
18.Bonde, S. and N. Zavazava, Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells, 2006. 24: p. 2192-201.
19.Janeway, C.A., et al., Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The major histocompatibility complex and its functions.
20.Swijnenburg, R.J., et al., In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev. 2008, 17: p. 1023-29.
21.Taylor, C.J., et al., Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005, 366: p. 2019-25.
22.Chung, Y.G., et al., Human somatic cell nuclear transfer using adult cells. Cell Stem Cell, 2014. 14: p. 777-80.
23.Tachibana, M., et al., Human embryonic stem cells derived by somatic cell nuclear transfer. Cell, 2013. 153: p. 1228-38.
24.Deuse, T., et al., SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. Cell Stem Cell, 2015. 16: p.33-38.
25.Guha, P., et al., Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 2013. 12: p. 407-12.
26.Zhao, T., et al., Immunogenicity of induced pluripotent stem cells. Nature, 2011. 474: p. 212-5.
27.Araki, R., et al., Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 2013. 494: p. 100-4.
28.Merling, R.K., et al., Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood, 2013. 121: p. e98- 107.
29.Jonathan, D.P., et al., Regulation of immune responses by mTOR. Annu Rev Immunol. 2012, 30: p. 39-68.
30.Pollizzi, K.N. and J.D. Powell, Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol, 2015. 36: p. 13-20.
31.Weichhart, T., M. Hengstschlager, and M. Linke, Regulation of innate immune cell function by mTOR. Nat Rev Immunol, 2015. 15: p. 599-614.
32.Sathaliyawala, T., et al., Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity, 2010. 33: p. 597-606.
33.Chen, H.F., et al., Derivation, characterization and differentiation of human embryonic stem cells: comparing serum-containing versus serum-free media and evidence of germ cell differentiation. Hum Reprod, 2007. 22: p. 567-77.
34.Huang, H.P., et al., Factors from human embryonic stem cell-derived fibroblast-like cells promote topology-dependent hepatic differentiation in primate embryonic and induced pluripotent stem cells. J Biol Chem, 2010. 285: p. 33510-9.
35.Burridge, P.W., et al., A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS ONE, 2011. 6: p. e18293.
36.Chen, H.F., et al., A reduced oxygen tension (5%) is not beneficial for maintaining human embryonic stem cells in the undifferentiated state with short splitting intervals. Hum Reprod, 2009. 24: p. 71-80.
37.Chen, H.F., et al., Novel autogenic feeders derived from human embryonic stem cells (hESCs) support an undifferentiated status of hESCs in xeno-free culture conditions. Hum Reprod, 2009. 24: p. 1114-25.
38.Ezashi, T., P. Das, and R.M. Roberts, Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci U S A, 2005. 102: p.4783-8.
39.Mo, C.F., et al., Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines. Stem Cell Res Ther, 2015. 6: p. 1.
40.Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods, 2001. 25: p. 402-8.
41.Lan, C.W., et al., Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Sci Rep, 2015. 5: p. 14994.
42.Huang, H.P., et al., Epithelial cell adhesion molecule (EpCAM) complex proteins promote transcription factor-mediated pluripotency reprogramming. J Biol Chem, 2011. 286: p. 33520-32.
43.Yu, C.W., et al., Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and angiogenic responses. Angiogenesis, 2016. 19: p. 95-106.
44.Eisen, M.B., et al., Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A, 1998. 95: p. 14863-8.
45.Ortutay, C. and M. Vihinen, Immunome knowledge base (IKB): an integrated service for immunome research. BMC Immunol, 2009. 10: p. 3.
46.Mostoslavsky, G., et al., Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther, 2005. 11: p. 932-40.
47.Wan, Y.Y., GATA3: a master of many trades in immune regulation. Trends Immunol, 2014. 35: p. 233-42.
48.Bhattacharya, S., et al., Prominin-1 is a novel regulator of autophagy in the human retinal pigment epithelium. Invest Ophthalmol Vis Sci, 2017. 58: p. 2366-87.
49.Fang, W., et al., Identification and activation of TLR4-mediated signaling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Sci Rep, 2017. 7: p.1663-1675.
50.Zhu, M., et al., Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells. Oncoscience, 2015. 2: p. 59-70.
51.Chang, J., et al., MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci USA, 2013. 110: p. 2270-75.
52.Su, X., et al., Interferon-r regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature Immunol, 2015. 16: p. 838-49.
53.Abhinand, C.S., et al., VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal, 2016. 10: p. 347-54.
54.Paterson, Y.Z., et al., Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther, 2014. 5: p. 90.
55.Magliocca, J.F., I.K. Held, and J.S. Odorico, Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev, 2006. 15: p. 707-17.
56.Menard, C., et al., Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet, 2005. 366: p. 1005-12.
57.Boyd, A.S., et al., Concise review: Immune recognition of induced pluripotent stem cells. Stem Cells, 2012. 30: p. 797-803.
58.Moulding, D.A., et al., Actin cytoskeletal defects in immunodeficiency. Immunol Rev, 2013. 256: p. 282-99.
59.Xie, X.H., et al., Post-transcriptional CD59 gene silencing by siRNAs induces enhanced human T lymphocyte response to tumor cell lysate-loaded DCs. Cell Immunol, 2012. 274: p1-11.
60.Tanaka, T., et al., IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014. 6: a016295.
61.Camby, I., et al., Galectin-1: a small protein with major functions. Glycobiology, 2006. 16: p. 137-57.
62.Jersmann, H.P.A., Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol and cell biol, 2005. 83: p.462-67.
63.Magister, S. and J. Kos, Cystains in immune system. J Cancer, 2013. 4: p.45-56.
64.Ryter, S.W., J. Alam and A.M.K. Choi, Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev, 2006. 86: p.583-650.
65.Abumaree, M., et al., Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev and Rep, 2012. 8: p. 375-92.
66.Cesari, M., M. Pahor, and R.A. Incalzi, Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther, 2012. 28: p. 72-91.
67.Yamagami, S., et al., Effects of TGF-β2 on immune response-related gene expression profiles in the human corneal endothelium. Immunol and Microbiol, 2004. 45: p. 515-529.
68.Dunn, S., et al., The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J, 2008. 409: p. 349-55.
69.Ponticelli, C. and H.J. Anders, Thrombospondin immune regulation and kidney. Nephrol Dial Transplant, 2017, gfw431. doi: 10.1093/ndt/gfw431.
70.Zobalova, R., et al., The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection? Antioxidant & Redox Signaling, 2011. 15: p. 2989-3002.
71.Corbeil, D., C.A. Fargeas, and J. Jaszai, CD133 might be a pan marker of epithelial cells with dedifferentiation capacity. Proc Natl Acad Sci U S A, 2014. 111: p. 1451-2.
72.Guerrini, M.M. and H. Takayanagi, The immune system, bone and RANKL. Arch Biochem Biophys, 2014. 561: p. 118-23.
73.Sims, J.E. and D.E. Smith, The IL-1 family: regulators of immunity. Nat Rev Immunol, 2010. 10: p.89-102.
74.Zhang, J., et al., Lack of MD2 expression in human corneal epithelia cells is an underlying mechanism of lipopolysaccharide (LPS) unresponsiveness. Immunol Cell Biol, 2009. 87: p. 141-48.
75.Liu, X.Y., et al., IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol, 2011. 187: p. 2559-68.
76.Ling, W., et al., Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res, 2014. 74: p. 1576-87.
77.Manning, B.D. and L.C. Cantley, AKT/PKB signaling: navigating downstream. Cell, 2007. 129: p. 1261-74.
78.Dibble, C.C., and B.D. Manning, Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol, 2013. 15: p. 555-64.
79.Lee, K.W., et al., Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev, 2010. 19: p. 557-68.
80.Singha, U.K., et al., Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem, 2008. 103: p. 434-46.
81.Ferrer, I.R., K. Araki, and M.L. Ford, Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant, 2011. 11: p. 654-9.
82.Zheng, Y., et al., A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol, 2007. 178: p. 2163-70.
83.Murray, P.J., et al., Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 2014. 41: p. 14-20.
84.Schlitzer, A., et al., Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nature Immunol, 2015. 16: p. 718-28.
85.Theisen, D. and K. Murphy, The role of cDC1s in vivo: CD8 T cell priming through cross-presentation [version 1; referee: 3 approved]. F1000Research. 2017. 6 (F1000 Faculty Rev): 98.
86.Elghetany, M.T. and J. Patel, Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol, 2002. 71: p. 348-9.
87.Liu, J.Q., et al., CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol, 2007. 178: p. 6227-35.
88.Wilson, B.J., Dose GATA3 act in tissue-specific pathways? A meta-analysis-based approach. J Carcinog, 2008. 7: p. 6.
89.Radtke, F., H.R. MacDonald, and F. Tacchini-Cottier, Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol, 2013. 13: p. 427-37.
90.Hernández-Hoyos, G., et al., GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation. Immunity, 2003. 19: p. 83-94.
91.Pandolfi, P.P., et al., Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet, 1995. 11: p. 40-4.
92.O''Garra, A. and L. Gabryšová, Correction: Transcription Factors Directing Th2 Differentiation: Gata-3 Plays a Dominant Role. J Immunol, 2016. 197: p. 4504.
93.Ting, C.N., et al., Transcription factor GATA-3 is required for development of the T-cell lineage. Nature, 1996. 384: p. 474-8.
94.Sakaguchi, S., et al., Regulatory T cells and immune tolerance. Cell, 2008. 133: p. 775-87.
95.Wohlfert, E.A., et al., GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest, 2011. 121: p. 4503-15.
96.Wang, Y., M.A. Su, and Y.Y. Wan, An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity, 2011. 35: p. 337-48.
97.Song, H., et al., Critical role for GATA3 in mediating Tie2 expression and function in large vessel endothelial cells. J Biol Chem, 2009. 284: p. 29109-24.
98.Lim, K.C., et al., Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genetics, 2000. 25: p. 209-12.
99.Takaku, M., et al., GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler. Genome Biol, 2016. 17: p. 36-51.
100.Yan, W., et al., GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal Transition. J. Biol Chem, 2010. 285: p. 14042-51.
101.Feng, Y., et al., CD103 expression is required for destruction of pancreatic islet allografts by CD8+ T cells. J Exp Med, 2002. 196: p. 877-86.
102.Allison, T.L., Immunosuppressive Therapy in Transplantation. Nurs Clin North Am, 2016. 51: p. 107-20.
103.Rong, Z., et al., An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell, 2014. 14: p. 121-30.
104.Sontag, C.J., et al., Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med, 2013. 2: p. 731-44.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top